In 1989, researchers proposed an intricate strategy in the field of adoptive cell therapy (ACT). Using the T-cell receptor (TCR) as a template, they replaced the coding sequence for the Vα and Vβ chains with the antigen- recognition domains from an antibody (VH and VL chains).

Emtricitabine (FTC) is an antiviral medication designed to diminish the presence of HIV in the body, thereby impeding or preventing harm to the immune system and the onset of AIDS-related illnesses. The precise mechanisms underlying emtricitabine's inhibition of HIV-1 replication in pre-exposure prophylaxis (PrEP) are not fully comprehended. This investigation delves into the impact of emtricitabine treatments in vitro, utilizing the susceptible Jurkat cell line.

Inflammatory bowel diseases (IBD) are inflammatory conditions characterized by chronic and recurrent intestinal inflammation. IBD affects nearly five million people worldwide, with an estimated prevalence of 245.3 cases per 100,000 people in the United States alone. The incidence of IBD is steadily increasing in industrialized countries and is appearing more often developing countries, contributing to its rise as a global disease burden.

Periodontitis and inflammatory bowel disease (IBD) are chronic inflammatory conditions driven by dysbiotic microbial communities that subvert host mucosal immunity. Central to the immunopathology of both diseases is the disruption of the balance between regulatory T cells (Tregs) and T helper 17 (Th17) cells, an equilibrium that governs tissue homeostasis versus inflammatory destruction. Polyamines, principally putrescine (PUT), spermidine (SPD), and spermine (SPN), are emerging as critical immunometabolic regulators that modulate the plasticity and functional identity of both cell populations.